Pyroptosis-Related Subtypes Predict the Response of Clear Cell Renal Cell Carcinoma to Targeted Therapy

被引:7
作者
Ma, Jinpeng [1 ,2 ]
Kang, Zhijian [1 ,2 ]
Yang, Guang [3 ]
Wang, Xinyue [1 ,2 ]
Si, Minggui [1 ,2 ]
Wang, Yuting [1 ,2 ]
Li, Guangbin [1 ,2 ]
Bai, Shiyu [1 ,2 ]
Zeng, Fanshu [1 ,2 ]
Li, Min [1 ,2 ]
Wang, Ziqi [1 ,4 ]
Wang, Lu [1 ,2 ]
Xu, Wanhai [1 ,4 ]
机构
[1] Harbin Med Univ, NHC Key Lab Mol Probes & Targeted Diag & Therapy, Harbin 150001, Heilongjiang, Peoples R China
[2] Harbin Med Univ, Heilongjiang Key Lab Sci Res Urol, Dept Urol, Hosp 4, Harbin 150081, Heilongjiang, Peoples R China
[3] Harbin Med Univ, Dept Neurosurg, Affiliated Hosp 1, Harbin 150001, Heilongjiang, Peoples R China
[4] Harbin Med Univ, Canc Hosp, Dept Urol, Harbin 150001, Heilongjiang, Peoples R China
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2023年 / 28卷 / 12期
基金
中国国家自然科学基金;
关键词
pyroptosis; immune microenvironment; immunotherapy; clear cell renal carcinoma; CHECKPOINT; EXPRESSION; BAP1; MICROENVIRONMENT; ANGIOGENESIS; SURVIVAL; MUTATION; SUBSETS; PBRM1;
D O I
10.31083/j.fbl2812334
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Pyroptosis plays a crucial role in anti-tumor immunity and in formation of the immune microenvironment. However, whether pyroptosis is involved in the progression of clear cell renal cell carcinoma (ccRCC) is still unclear. Personalized treatment of ccRCC requires detailed molecular classification to inform a specific therapy. Methods: Molecular subtyping of ccRCC was performed based on consensus clustering of pyroptosis-related genes. The characteristics of these molecular subtypes were explored at the genome, transcriptome and protein levels. Single-cell RNA sequencing and CIBERSORT analysis were used to analyse the immune microenvironment of ccRCC, while Lasso regression was used to develop a prediction model based on hub genes. Expression of the pyroptosis-related gene GSDMB was also investigated at the tissue and cellular levels. Results: Two molecular subtypes were identified based on the clustering of pyroptosis-related genes. Cluster 1 was associated with activation of classical oncogenic pathways, especially the angiogenesis pathway. Cluster 2 was associated with activation of immune-related pathways and high levels of immunosuppressive cells, exhausted CD8+ T cells, and tumor-associated fibroblast infiltration. Clusters 1 and 2 were thus defined as the angiogenic and inflamed subtypes, respectively. The two subtypes were predictive of the response of ccRCC to anti-angiogenic therapy and immunotherapy, with Cluster 1 patients benefiting from anti-angiogenic therapy and Cluster 2 patients showing better response to anti-PD1 inhibitor therapy. Furthermore, a 9-gene expression signature (HJURP, NUF2, KIF15, MELK, TPX2, PLK1, CDCA3, CTLA4, FOXP3) was identified that could predict outcome and response to immune checkpoint blockade therapy in test cohorts. Finally, GSDMB was found to be involved in the development of renal clear cell carcinoma. Conclusions: These results on pyroptosis-related genes in ccRCC provide a theoretical basis for understanding molecular heterogeneity and for the development of individualized treatment strategies.
引用
收藏
页数:14
相关论文
共 56 条
  • [11] Downregulation of GSDMD attenuates tumor proliferation via the intrinsic mitochondrial apoptotic pathway and inhibition of EGFR/Akt signaling and predicts a good prognosis in non-small cell lung cancer
    Gao, Jianwei
    Qiu, Xiangyu
    Xi, Guangmin
    Liu, Hongbing
    Zhang, Fang
    Lv, Tangfeng
    Song, Yong
    [J]. ONCOLOGY REPORTS, 2018, 40 (04) : 1971 - 1984
  • [12] Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
    Giraldo, Nicolas A.
    Becht, Etienne
    Pages, Franck
    Skliris, Georgios
    Verkarre, Virginie
    Vano, Yann
    Mejean, Arnaud
    Saint-Aubert, Nicolas
    Lacroix, Laetitia
    Natario, Ivo
    Lupo, Audrey
    Alifano, Marco
    Damotte, Diane
    Cazes, Aurelie
    Triebel, Frederic
    Freeman, Gordon J.
    Dieu-Nosjean, Marie-Caroline
    Oudard, Stephane
    Fridman, Wolf H.
    Sautes-Fridman, Catherine
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (13) : 3031 - 3040
  • [13] Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Glynne-Jones, R.
    Wyrwicz, L.
    Tiret, E.
    Brown, G.
    Rodel, C.
    Cervantes, A.
    Arnold, D.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 : 22 - 40
  • [14] GLI1 regulates a novel neuropilin-2/61 integrin based autocrine pathway that contributes to breast cancer initiation
    Goel, Hira Lal
    Pursell, Bryan
    Chang, Cheng
    Shaw, Leslie M.
    Mao, Junhao
    Simin, Karl
    Kumar, Prashant
    Vander Kooi, Craig W.
    Shultz, Leonard D.
    Greiner, Dale L.
    Norum, Jens Henrik
    Toftgard, Rune
    Kuperwasser, Charlotte
    Mercurio, Arthur M.
    [J]. EMBO MOLECULAR MEDICINE, 2013, 5 (04) : 488 - 508
  • [15] GSVA: gene set variation analysis for microarray and RNA-Seq data
    Haenzelmann, Sonja
    Castelo, Robert
    Guinney, Justin
    [J]. BMC BIOINFORMATICS, 2013, 14
  • [16] Batch effects in single-cell RNA-sequencing data are corrected by matching mutual nearest neighbors
    Haghverdi, Laleh
    Lun, Aaron T. L.
    Morgan, Michael D.
    Marioni, John C.
    [J]. NATURE BIOTECHNOLOGY, 2018, 36 (05) : 421 - +
  • [17] USP24-GSDMB complex promotes bladder cancer proliferation via activation of the STAT3 pathway
    He, Haiqing
    Yi, Lu
    Zhang, Bin
    Yan, Bin
    Xiao, Ming
    Ren, Jiannan
    Zi, Dong
    Zhu, Liang
    Zhong, Zhaohui
    Zhao, Xiaokun
    Jin, Xin
    Xiong, Wei
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2021, 17 (10): : 2417 - 2429
  • [18] Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials
    Heng, D. Y. C.
    Choueiri, T. K.
    Rini, B. I.
    Lee, J.
    Yuasa, T.
    Pal, S. K.
    Srinivas, S.
    Bjarnason, G. A.
    Knox, J. J.
    MacKenzie, M.
    Vaishampayan, U. N.
    Tan, M. H.
    Rha, S. Y.
    Donskov, F.
    Agarwal, N.
    Kollmannsberger, C.
    North, S.
    Wood, L. A.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 (01) : 149 - 154
  • [19] Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
    Heng, Daniel Y. C.
    Xie, Wanling
    Regan, Meredith M.
    Warren, Mark A.
    Golshayan, Ali Reza
    Sahi, Chakshu
    Eigl, Bernhard J.
    Ruether, J. Dean
    Cheng, Tina
    North, Scott
    Venner, Peter
    Knox, Jennifer J.
    Chi, Kim N.
    Kollmannsberger, Christian
    McDermott, David F.
    Oh, William K.
    Atkins, Michael B.
    Bukowski, Ronald M.
    Rini, Brian I.
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) : 5794 - 5799
  • [20] Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types
    Iglesia, Michael D.
    Parker, Joel S.
    Hoadley, Katherine A.
    Serody, Jonathan S.
    Perou, Charles M.
    Vincent, Benjamin G.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (11):